Choi Chong Won, Lee Ji Su, Yu Da-Ae, Kim Bo Ri, Youn Sang Woong
Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Ann Dermatol. 2019 Feb;31(1):44-50. doi: 10.5021/ad.2019.31.1.44. Epub 2019 Jan 2.
The efficacy and safety of etanercept in the treatment of psoriasis has been proven, and the drug was approved for the treatment of moderate to severe psoriasis. However, there have been few studies that have presented real-world data focused on concomitant treatment during etanercept treatment, and the switching pattern after discontinuation of etanercept.
To reveal the real-world treatment pattern of etanercept-based psoriasis treatment and to investigate the switching pattern after withdrawal of etanercept.
We enrolled 66 patients with psoriasis who were treated with etanercept. We collected data regarding the demographic characteristics of the patients, etanercept treatment schedules, and other treatments administered during the etanercept treatment period. We also investigated the treatment pattern after the discontinuation of etanercept with emphasis on the drug-free interval and the administered treatment modalities.
The mean treatment duration was 22.7±26.1 months and the mean number of etanercept injections was 21.5±27.9. Thirty-six patients were administered concomitant systemic medication or phototherapy. After discontinuation of etanercept, 54 patients were followed up and 34 of these patients were administered other systemic medication or phototherapy; phototherapy and cyclosporine was the most commonly administered treatment modality and 27.4% of treatments used biologics.
The treatment schedule for etanercept was modified according to the severity of psoriasis and concomitant treatment was administered to improve the effectiveness of treatment in the patients enrolled in the study. We also found that most patients required other treatment modalities to control psoriasis during the period of etanercept treatment.
已证实依那西普治疗银屑病的有效性和安全性，该药物已获批用于治疗中度至重度银屑病。然而，很少有研究提供聚焦于依那西普治疗期间联合治疗以及依那西普停药后转换模式的真实世界数据。
揭示基于依那西普的银屑病治疗的真实世界治疗模式，并调查依那西普停药后的转换模式。
我们纳入了66例接受依那西普治疗的银屑病患者。我们收集了患者的人口统计学特征、依那西普治疗方案以及依那西普治疗期间给予的其他治疗的数据。我们还调查了依那西普停药后的治疗模式，重点关注无药间隔期和给予的治疗方式。
平均治疗持续时间为22.7±26.1个月，依那西普注射的平均次数为21.5±27.9次。36例患者接受了联合全身用药或光疗。依那西普停药后，对54例患者进行了随访，其中34例患者接受了其他全身用药或光疗；光疗和环孢素是最常用的治疗方式，27.4%的治疗使用了生物制剂。
依那西普的治疗方案根据银屑病的严重程度进行了调整，并给予联合治疗以提高本研究中纳入患者的治疗效果。我们还发现，大多数患者在依那西普治疗期间需要其他治疗方式来控制银屑病。
